Search clinical trials for: Sitagliptin (Januvia)

Total 860 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Diabetes Mellitus, Type 2

United States, France, India, Philippines
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Belgium, Brazil, Canada, Czech Republic, Finland, Germany, Greece, Italy, Korea, Republic of, Mexico, Netherlands, Norway, Peru, Russian Federation, Slovakia, Spain, Taiwan
Brigham and Women's Hospital

Completed

Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims

Diabetes

United States
University of Erlangen-Nürnberg Medical School

Completed

Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.

Type 2-diabetes

Germany
Ram Weiss

Unknown

DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic Fibrosis

Cystic Fibrosis

Israel
Ram Weiss

Unknown

Cystic Fibrosis Related Diabetes

Cystic Fibrosis

Israel
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

Diabetes Mellitus, Type 2

United States
University of Sao Paulo

Completed

Evaluation of Root Coverage by Connective Graft and Different Root Conditioning Methods

Gingival Recession

Brazil
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Comprehensive Add on Study in Japan

Diabetes Mellitus, Type 2

Japan
George Washington University
Boehringer Ingelheim

Completed

Linagliptin's Effect on CD34+ Stem Cells

Type 2 Diabetes | Impaired Renal Function

United States
Heart Care Foundation
Fondazione dell'Associazione Medici Diabetologi

Completed

Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry (DYDA2)

Diabetes Mellitus, Type 2 | Left Ventricular Systolic Dysfunction

Italy
George Washington University
AstraZeneca

Completed

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

Type 2 Diabetes

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Diabetes Mellitus, Type 2

Korea, Republic of
Royal Devon and Exeter NHS Foundation Trust
NIHR Exeter Clinical Research Facility

Completed

Glucose Response, Excursions And Treatment (GREAT) Study (GREAT)

Type 2 Diabetes

United Kingdom
AstraZeneca
Bristol-Myers Squibb

Completed

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications (SAVOR- TIMI 53)

Type 2 Diabetes Mellitus

Sweden, United States, Australia, Brazil, Czech Republic, Italy, Mexico, Peru, Poland, Russian Federation, South Africa, Spain, United Kingdom, Germany, China, Hungary, Netherlands, Canada, Hong Kong, Argentina, Chile, France, Israel, Puerto Rico and more
AstraZeneca
Bristol-Myers Squibb

Completed

Saxagliptin Triple Oral Therapy

Type 2 Diabetes

Korea, Republic of, United Kingdom, Australia, Canada, Thailand, India
AstraZeneca
Bristol-Myers Squibb

Completed

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

Type 2 Diabetes

Croatia, United States, Bulgaria, Czech Republic, Poland, Russian Federation, Belarus, Estonia, Germany, Hungary, Latvia, Lithuania, Romania, Ukraine
AstraZeneca
Bristol-Myers Squibb

Completed

Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin

Type 2 Diabetes

China
AstraZeneca

Completed

Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.

Healthy

Russian Federation
University of Erlangen-Nürnberg Medical School

Completed

Effects of Saxagliptin on Endothelial Function (ESENDI)

Diabetes Mellitus Type 2

Germany
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control

Type 2 Diabetes

India
Oregon Health and Science University

Suspended

Effects of DPP-4 Inhibition on Triglycerides

Type 2 Diabetes | Hypertriglyceridemia

United States
ikfe-CRO GmbH
MLM Medical Labs GmbH; Ikfe GmbH

Completed

Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria

Albuminuria | Arterial Hypertension

Germany
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers

Healthy
AstraZeneca
Bristol-Myers Squibb

Completed

52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period

Type 2 Diabetes

Korea, Republic of, Russian Federation, United Kingdom, Vietnam, Germany, Hungary, Finland, Norway, Netherlands, Slovakia, India
University of Miami

Withdrawn

Effects of DPP4 Inhibition on COVID-19

Coronavirus Infection | Type 2 Diabetes

United States
Baylor College of Medicine

Terminated

Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation

Impaired Glucose Tolerance

United States
Postgraduate Institute of Medical Education and...

Unknown

Incretin Axis in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

India
AstraZeneca

Completed

Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

Type 2 Diabetes

United States, Mexico, Puerto Rico, Israel, Sweden, Italy, Philippines, Argentina
Boehringer Ingelheim

Completed

Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers

Healthy
University Hospital, Lille
I-site University Lille North Europe

Withdrawn

Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19 (HYdILIC)

Sars-CoV2
Samsung Medical Center

Completed

Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency (DA1229)

Renal Insufficiency | Albuminuria | Type2 Diabetes Mellitus

Korea, Republic of
Boehringer Ingelheim

Completed

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Diabetes Mellitus, Type 2

United States, Argentina, Hungary, India, Japan, Poland, Russian Federation
Boehringer Ingelheim

Completed

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Diabetes Mellitus, Type 2

United States, Australia, Hong Kong, Israel, New Zealand, Ukraine
University of Washington
Medtronic; Abbott; American Diabetes Association

Completed

Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management (CANDY-CANE)

Chronic Kidney Diseases | Type 2 Diabetes

United States
Brigham and Women's Hospital

Completed

Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

Diabetes Mellitus

United States
Medical University of Graz

Completed

Incretin Effect on the Immunological Phenotype

Type 1 Diabetes

Austria
AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes (PROMPT)

Type 2 Diabetes Mellitus

France, Italy, Turkey, Germany, United Kingdom, Belgium, Spain
AstraZeneca
Bristol-Myers Squibb

Completed

An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes (SCORE)

Type 2 Diabetes

United States, Peru, Mexico, Colombia, Costa Rica
AstraZeneca

Completed

Study of Multiple Doses of Saxagliptin (BMS-477118)

Type 2 Diabetes Mellitus
University of Padova

Completed

Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Type 2 Diabetes | Chronic Renal Failure

Italy
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects

Hepatic Insufficiency
University of Nevada, Reno
Augusta University

Completed

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

Schizophrenia

United States
Phoenix VA Health Care System
Bristol-Myers Squibb

Completed

Effects of Saxagliptin on Adipose Tissue Inflammation in Humans

Type 2 Diabetes Mellitus (T2DM)

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

Healthy

Germany
dr. DJ Mulder
Boehringer Ingelheim

Completed

Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes (RELEASE)

Type 2 Diabetes Mellitus

Netherlands
AstraZeneca

Completed

A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas

Diabetes

Korea, Republic of, Mexico, Taiwan, United States, Argentina, Brazil, Puerto Rico, South Africa, Hong Kong, Israel, Singapore, Peru, Philippines
The University of Texas Medical Branch, Galveston

Withdrawn

New Treatment for Donor Sites (Donors)

Burn

Search clinical trials for: Sitagliptin (Januvia)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations